Strategies for Determining Treatment Flow of CAR T-Cell Therapy and HSCT in Pediatric ALL (ICBMT 2026) - Oct 8, 2026 - Abstract #SS02-2; Pres time: Sep 17, 2026; 03:00 PM - 03:30 PM; Location: Room C(2F); "Patients treated with CD28-based CAR T-cell products appear to derive a survival advantage from HSCT consolidation, whereas outcomes following 4-1BB–based products such as tisagenlecleucel are more heterogeneous, with a subset achieving long-term remission without transplantation...Among transplant-naïve patients, HSCT may be appropriate for individuals with high pre-treatment disease burden, prior failure of blinatumomab, adverse biological features associated with limited salvage options, or readily available donors and willingness to proceed with transplantation...Ultimately, treatment sequencing should be individualized through comprehensive assessment of disease characteristics, prior transplant history, donor availability, CAR T-cell persistence, MRD status, and patient-specific comorbidities. As prospective randomized data remain limited, future studies are needed to refine risk-adapted algorithms that optimize the use of CAR T-cell therapy and HSCT..."
CAR T-Cell Therapy • Clinical • Acute Lymphocytic Leukemia • B Acute Lymphoblastic Leukemia • Bone Marrow Transplantation • Graft versus Host Disease • Hematological Malignancies • Immunology • Leukemia • Pediatrics
|